Huayu Yang, Ph.D.
Associate researcher, Peking Union Medical College Hospital
dolphinyahy@hotmail.com
Biography:
Dr. Huayu Yang is an associate researcher in the Department of Liver Surgery at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences. She graduated from the Peking University Health Science Center (PUHSC) in 2002 and obtained her PhD degree in pharmacology from PUHSC in 2007. In 2011, she completed postdoctoral training in PUMCH under the supervision of Prof. Jiefu Huang. After that, she worked as an assistant researcher and associate researcher in the Department of Liver Surgery, PUMCH. The recent research is focusing on the clinical basic research of liver cancer serum biomarker GP73 and the application of 3D bioprinting technology in liver disease and drug research. She is the PIs of several research projects and has published more than 60 articles in domestic and international journals. Dr. Yang won the third prize of the China Medical Science and Technology Award (ranked second).
Topic title: Implication of Personalized Treatment on 3D Printed Long-Term Regenerated HCC Model
Abstract: Hepatocellular carcinoma is the most common primary malignant tumor of the liver. In recent years, the treatment strategy of liver cancer has been continuously improved, and the overall 5-year survival rate has been significantly increased. However, the sensitivity of individual cases to targeted drugs is still very different, and the difference is very far. Hepatocellular carcinoma is highly heterogeneous, and the efficacy of targeted drugs varies greatly between individuals and before and after treatment. There is an urgent need for individualized treatment for liver cancer. 3D bioprinted tumor model is a new method in the field of individualized treatment. This study is the first to use 3D bioprinting method to successfully establish a variety of in vitro tumor individualized models which can be long-term cultured. The model can retain the histological features, mutation mode and gene expression characteristics of parental liver cancer and can be used for screening and evaluation of various targeted drugs. It is a reliable method to achieve individualized treatment of liver cancer.